Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Rick Doblin · Said 5 Jan 2024 · doblin-0206
Quote
Not a forecast
“Helena is the right partner to help position Lykos in its transition from a research-focused public benefit company, wholly owned by a nonprofit, to a PBC with mission-aligned investors focused on obtaining FDA approval and insurance coverage for prescription use of MDMA-assisted therapy by appropriate patients with PTSD.”
MAPS post announcing the $100M Series A led by Helena and the renaming of MAPS PBC to Lykos Therapeutics. Doblin frames Lykos' goal as obtaining FDA approval and insurance coverage.
Descriptive, retrospective, or a statement of preference; no future state asserted.